Document:

<PAGE>

                                                                    Exhibit 10.2

                           Amendment  and Supplement
                              To Finder Agreement

                                 April 6, 2000

This Amendment and Supplement (this "Supplement") amends and supplements the
Finder Agreement dated February 29, 2000 entered into by and between Endorex
Corporation (the "Company") and Paramount Capital, Inc. (the "Finder").
Capitalized terms used, but not defined, in this Supplement shall have the
meanings given to them in the Finder Agreement unless the context otherwise
requires.

A. Paragraph 1 of the Finder Agreement is hereby replaced in its entirety to
provide as follows:

     1. Paramount will introduce the Company to "accredited investors" as
defined in Rule 501 of Regulation D promulgated under the Act for the purchase
of Units. Each "Unit" shall consist of (i) 21,164 shares of common stock of the
Company, par value $.001 per share (the "Common Stock") and (ii) a five year
warrant (collectively, the "Warrants") to purchase 5,291 shares of Common Stock,
such warrants to be exercisable, in whole or in part, at any time prior to the
fifth anniversary of the date of issuance at an exercise price equal to $5.91
per share of Common Stock underlying such Warrants (the Common Stock, the
Warrants, and the Common Stock issuable upon the exercise of the Warrants are
sometimes herein collectively referred to as the "Securities"). The purchase
price of each Unit shall be $100,000. The Company will sell a maximum number of
Units which would include up to 1,850,000 shares of Common Stock (exclusive of
the Warrants and any Paramount Warrants (as defined below)) (the "Maximum
Offering"). The sale of any Units is contingent upon the Company making sales of
a number of Units which would provide aggregate gross proceeds to the Company of
at least $2,000,000 (the "Minimum Offering"). "Trading Day" shall mean a day on
which the American Stock Exchange is open for the transaction of business.

B. Paragraph 9 of the Finder Agreement is hereby replaced in its entirety to
provide as follows:

     9. Upon consummation of the Offering contemplated hereby, the Company will,
in consideration of the services rendered by Paramount in connection with the
Offering, issue to Paramount and/or its designees for no additional
consideration, warrants (the "Paramount Warrants") to acquire a number of shares
of Common Stock equal to the sum of (i) ten percent (10%) of the number of
shares of Common Stock included in the Units sold in the Offering and (ii) ten
percent (10%) of the number of shares of Common Stock issuable upon exercise of
Warrants contained in the Units sold in the Offering, exercisable for a period
of seven (7) years commencing six (6) months after the closing of the Offering
at an exercise price equal to $5.25 per share. The Paramount Warrants cannot be
exercised, transferred, sold, assigned or hypothecated for six (6) months except
that they may be assigned in whole or in part during such period to any NASD
member participating in the Offering or any officer or employee of Paramount or
any such NASD member. The Paramount Warrants will contain a cashless
<PAGE>

exercise feature, anti-dilution protection and the right to have the Common
Stock issuable upon exercise thereof included on the Shelf Registration
Statement. In the event that the closing bid price for any 20 consecutive
Trading Days is at least 250% of the exercise price of Paramount Warrants, then
upon 30 days prior written notice to Paramount, the Company shall have the right
to redeem Paramount Warrants at a price equal to the exercise price if such
Paramount Warrants have not been exercised prior to the expiration of such 30
day period.

     In witness whereof, the parties have caused this Amendment to be executed
as of the date first set forth above.

                                              PARAMOUNT CAPITAL, INC.

                                              By:______________________________
                                              Name:  Lindsay A. Rosenwald, M.D.
                                              Title: Chairman

The foregoing is in conformity
with our understanding:

ENDOREX CORPORATION

By:__________________________________
Name:  Mr. Michael S. Rosen
Title: President and Chief Executive Officer<PAGE>

                                                                    Exhibit 10.3

                          FINANCIAL ADVISORY AGREEMENT

     THIS AGREEMENT (the "Agreement"), made and entered into this 25th day of
October, 1999, by and between Endorex Corporation, a Delaware corporation
(hereinafter termed the "Company"), on one hand; and Paramount Capital, Inc.
(hereafter "Advisor") on the other hand.

                              W I T N E S S E T H:

     WHEREAS, the Company is engaged in, among other things, the development and
marketing of drug delivery systems and cancer therapy, and

     WHEREAS, Advisor has agreed to provide certain financial advisory services
to the Company upon the following terms and conditions.

     NOW, THEREFORE, for and in consideration of the terms and conditions
hereinafter set forth, the Parties hereto agree as follows:

1.   TERM

     The term of this Agreement will be for twelve (12) months from and after
the 25th day of October, 1999, unless earlier terminated (i) upon mutual
agreement of the parties, (ii) at any time by Advisor upon written notice to the
Company, (iii) by the Company upon written notice to Advisor on or before April
25, 2000, subject to its payment of the Termination Fee as set forth in Section
2(a), or (iv) by the Company upon written notice to Advisors at any time after
April 25, 2000 (the "Term").

2.   COMPENSATION

     (a)  The Company will pay to Advisors ongoing fees for Services (as
described in Section 3) at the rate of $5,000 per month, with the first three
(3) months payable at the time of execution of this Agreement. If the Company
terminates the agreement prior to April 25, 2000, the Company shall be obligated
to continue monthly payments until April 25, 2000.

     (b)  Upon entering into this Agreement, Advisor, or its designees, will be
granted option to purchase 36,000 shares of Endorex Corporation Common Stock, at
an exercise price of $2.54 per share (hereinafter collectively referred to as
the "Vested Options"), to vest as follows: (i) 25% (9,000 shares) shall vest
upon execution of this Agreement (hereinafter "First Vested Options"); (ii) an
additional 25% (9,000 shares) shall vest six (6) months from the date of
execution of this Agreement (hereinafter "Second Vested Options"); and (iii) the
remaining 50% (18,000 shares) shall vest twelve (12) months from the date of
execution of this Agreement (hereinafter "Third Vested Options").

     (c)  Advisor can exercise the Vested Options as follows: (i) the First
Vested Options can be exercised twelve (12) months from the execution of this
Agreement; (ii) the Second Vested Options can be exercised 18 months from the
execution of this Agreement; and (iii) the
<PAGE>

Third Vested Options can be exercised twenty-four (24) months from the execution
of this Agreement. If the Company terminates this Agreement prior to the end of
six (6) months, pursuant to paragraph 1 above, the Company shall be obligated to
vest the Second Vested Options (9,000 shares) to Advisor. The options will
expire ten (10) years after the date of this Agreement. In addition, the Vested
Options shall contain a cashless exercise feature.

     (d)  Upon entering into this Agreement, Advisor, or its designees, will be
granted options to purchase an additional 10,000 shares of Endorex Corporation
Common Stock at an exercise price of $2.54 per share to be fully vested upon
grant. The options will expire one year after the date of this Agreement and
will be subject to the Company's right to repurchase such options for $50,000.

     (e)  Upon the Closing of each Investment of newly issued stock (as defined
below) during the Term, the Company shall pay to Advisor a fee in an amount of
no more than seven percent (7%) of the aggregate value of such Investment and
shall issue to Advisor warrants to purchase an amount of securities of no more
than ten percent (10%) of the newly-issued securities sold as part of such
Investment at an exercise price equal to one-hundred-ten percent (110%) of the
price of such securities, exercisable until seven (7) years from the date of
issuance of such warrants. For the purposes of this Agreement, an "Investment"
shall mean any purchase of newly-issued securities of the Company which is made
during the Term or during the twelve-month period following the term by an
investor first introduced to the Company by or through Advisor during the Term;
provided, however, that if the investor held an investment prior to the date of
this Agreement, such fee will be no more than 5% of the aggregate value of such
investment plus warrants as above.

     (f)  The Company also agrees to pay the Advisor in cash all out of pocket
expenses incurred by Advisor in providing its services hereunder, including
reasonable fees and disbursements of Advisor's counsel. Such expenses are to be
paid upon submission of a bill or bills by Advisor from time to time. If any
individual expense shall exceed five thousand dollars ($5,000.00), Paramount
agrees to obtain prior written authorization for such expense from Company.

3.   SERVICES

     "Services" will include the following: (1) identifying and contacting
potential investors in the Company's securities, (2) organizing meetings with
potential investors and (3) participating in meetings and discussions with
potential investors regarding the Company. Advisors will use their best efforts
in providing the Services. Advisors will be engaged until the engagement is
terminated as specified herein.

4.   ASSIGNMENT

     Advisor may not assign its rights or obligations under this Agreement
without the written consent of the Company. Neither this Agreement nor any
provision hereof may be changed, waived, discharged, or terminated other than by
an instrument in writing signed by the party against which enforcement of the
change, waiver, discharge or termination is being asserted.

                                       2
<PAGE>

5.  ENTIRE AGREEMENT

     This Agreement contains all the terms and conditions agreed upon by the
parties relating to the subject matter of this Agreement and supersedes in full
and replaces the Financial Advisory Agreement between the Company and Paramount
Capital, Inc. dated October 16, 1997.  If any provision of this Agreement is
held unenforceable or inoperative by any court, either whole or in part the
remaining provisions shall be deemed severable and unaffected and shall continue
in full force and effect.

6.  MISCELLANEOUS

     (a)  Relationship to Parties. Advisor is an independent contractor of the
Company. Nothing in this Agreement shall be construed as creating an employer-
employee relationship or a guarantee of future employment or engagement. Advisor
further agrees to be responsible for all of its federal and state taxes,
withholding, social security, insurance, and other benefits except as otherwise
expressly set forth herein.

     (b)  Other Activities. Advisor is free to engage in other independent
contracting activities. Advisor also agrees not to induce or attempt to
influence, directly or indirectly, any employee at the Company to terminate
his/her employment and work for Advisor or any other person.

     (c)  Conflicts. Advisor represents and warrants that neither its agreement
to perform, nor its performance of the Services under to this Agreement will
violate any legal or regulatory statute, rule or requirement, or any agreement
or obligation between such Advisor and any third party.

     (d)  Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York without regard to conflict of
law principles.

     (e)  Remedy for Breach. The parties hereto agree that, in the event of
breach or threatened breach of any covenants of Advisor, the damage or imminent
damage to the value and the goodwill of the Company's business shall be
inestimable, and that therefore any remedy at law or in damages shall be
inadequate. Accordingly, the parties hereto agree that the Company shall be
entitled to injunctive relief against Advisor in the event of any by Advisor, in
addition to any other relief (including damages) available to the Company under
this Agreement or under law.

     (f)  Survival. Sections 6(e) and 6(f) shall survive termination of this
Agreement.

                                       3
<PAGE>

     IN WITNESS WHEREOF, the Parties hereto set their hands this 25th day of
October 1999.

                                  ENDOREX CORPORATION

                                  By:  /s/ Michael S. Rosen
                                      ------------------------
                                      Michael S. Rosen, President/CEO

                                  PARAMOUNT CAPITAL, INC.

                                  By:  /s/ Lindsay Rosenwald
                                      -----------------------
                                      Lindsay Rosenwald, M.D., Chairman

                                       4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00009-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00009-of-00352.parquet"}]]